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Abstract
Among people at genetic risk of schizophrenia, those who use cannabis show smaller thalamic and 
hippocampal volumes. We evaluated this relationship in people at clinical high risk (CHR) of 
psychosis. The Alcohol and Drug Use Scale was used to identify 132 CHR cannabis users, the 
majority of whom were non-dependent cannabis users, 387 CHR non-users, and 204 healthy 
control non-users, and all participants completed magnetic resonance imaging scans. Volumes of 
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the thalamus, hippocampus and amygdala were extracted with FreeSurfer, and compared across 
groups. Comparing all CHR participants with healthy control participants revealed no significant 
differences in volumes of any ROI. However, when comparing CHR users to CHR non-users, a 
significant ROI × Cannabis group effect emerged: CHR users showed significantly smaller 
amygdala compared to CHR non-users. However, when limiting analysis to CHR subjects who 
reported using alcohol at a ‘use without impairment’ severity level, the amygdala effect was non-
significant; rather, smaller hippocampal volumes were seen in CHR cannabis users compared to 
non-users. Controlling statistically for effects of alcohol and tobacco use rendered all results non-
significant. These results highlight the importance of controlling for residual confounding effects 
of other substance use when examining the relationship between cannabis use and neural structure.
Keywords
Amygdala; hippocampus; marijuana; magnetic resonance imaging; neuroanatomy; schizophrenia; 
thalamus
1. Introduction
Cannabis is the most extensively used illegal substance in people with schizophrenia. A 
recent review of the literature established that this is also true in people at clinical high risk 
(CHR) of developing psychosis (Addington et al., 2014), that is, individuals who present 
with attenuated or brief intermittent psychotic symptoms, or have a genetic risk for 
psychosis and decline in functioning. There is also some research implicating cannabis as 
one important factor in the onset of psychosis (Caspi et al., 2005; Fusar-Poli et al., 2012a; 
Kuepper et al., 2011; Moore et al., 2007). Prospective data suggests that among people at 
CHR of psychosis who use cannabis, those with higher baseline use severity (Buchy et al., 
2015a) and frequency (Valmaggia et al., 2014), and a first use prior to age of 15 (Arseneault 
et al., 2002; Valmaggia et al., 2014) all confer a greater risk of transition to psychosis.
Recent work has established a link between cannabis use and subcortical volumes in people 
with schizophrenia. The thalamus, hippocampus and amygdala have been of particular 
interest as people with schizophrenia show volumetric reductions in these areas relative to 
healthy people (Bora et al., 2011; Chan et al., 2011; Ellison-Wright et al., 2008) and these 
regions are rich in cannabinoid 1 (CB1) receptors in the human brain (Glass et al., 1997). 
For example, chronic, heavy cannabis use has been associated with volumetric reductions in 
the hippocampus and amygdala (Lorenzetti et al., 2015). People with schizophrenia and a 
cannabis use disorder show cannabis-related shape differences in thalamus, striatum and 
globus pallidus, compared to patients without a cannabis use disorder (Smith et al., 2014), 
and cannabis users with schizophrenia show marked hippocampal shape deflation compared 
to healthy controls (Solowij et al., 2013). Several studies have established a link between 
subcortical volumes and cannabis use in people at familial risk of schizophrenia. One study 
reported that those who used cannabis frequently (i.e. at least once a month but not more 
than three times per week) had an enlarged third ventricle relative to other use frequencies, 
which could reflect gray matter loss in the adjacent anterior medial thalamus (Welch et al., 
2011a). A second study used manual tracing technique and showed that people at familial 
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risk of schizophrenia who consumed cannabis over a 2-year period showed bilateral volume 
loss in the thalamus, but not in the hippocampus or amygdala, compared to a non-exposed 
group (Welch et al., 2011b). A third study used an automated tensor-based morphometry 
analysis to detect gray matter loss in right anterior hippocampus (Welch et al., 2013). 
Together these finding suggest that people at familial risk of schizophrenia are particularly 
sensitive to the risk-modifying effects of cannabis on thalamic and perhaps hippocampal 
structure, but not on amygdala volumes. Very recent evidence suggests that thalamic 
functional connectivity may be impacted by cannabis use patterns in youth at clinical high 
risk of psychosis (Buchy et al., 2015b); however, it is unknown whether thalamic and other 
subcortical volumes are associated with cannabis use in this population. The CHR 
population offers a unique opportunity to study the relationship between cannabis use and 
subcortical volumes in people who are more likely to transition to psychosis than people at 
familial risk of psychosis or healthy people.
Based on the literature described above, the aim of the current report was to evaluate 
thalamic, hippocampal and amygdala volumes in CHR participants who used cannabis at 
baseline compared to CHR non-users. We hypothesized that CHR cannabis users would 
show significantly smaller thalamic and hippocampal volumes compared to CHR 
participants who did not use cannabis.
2. Methods
2.1 Participants
Participants were recruited for the second phase of the multi-site North American Prodrome 
Longitudinal Study (NAPLS-2) (Addington et al., 2012), a 2-year longitudinal study which 
was established to investigate predictors and mechanisms of transition to psychosis. The 
final NAPLS sample consists of 764 CHR participants and 280 healthy controls (HC). The 
present paper reports on the 519 CHR participants in NAPLS-2 who provided baseline 
magnetic resonance (MR) scans and also completed a baseline assessment on cannabis use, 
as well as 204 HC participants who were not using cannabis at a baseline and provided MR 
scans. All CHR participants were required to meet the Criteria of Prodromal Syndromes 
(COPS) using the Structured Interview for Prodromal-Risk Syndromes (SIPS) (McGlashan 
et al., 2010).
Participants were excluded if they met criteria for any current or lifetime axis I psychotic 
disorder, IQ<70, past or current history of central nervous system disorder or DSM-IV 
criteria for current substance dependence disorder. HC participants were also excluded if 
they had a first-degree relative with a current or past psychotic disorder. A more detailed 
description of ascertainment, inclusion and exclusion criteria, and participant details is 
provided elsewhere (Addington et al., 2012).
2.2 Measures
The SIPS and the Scale of Prodromal Symptoms (SOPS) (McGlashan et al., 2010) were 
used to assess criteria for a prodromal syndrome and severity of attenuated positive 
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symptoms. Post-training agreement on determining the prodromal diagnoses was excellent 
(kappa=0.90) (Addington et al., 2012).
Cannabis use in the last month was rated using the Alcohol and Drug Use Scale (AUS/DUS) 
(Drake et al., 1996) which records severity (1=abstinent, 2=use without impairment, 
3=abuse, 4=dependence) and frequency of use (0=no use, 1=once or twice per month, 2=3–4 
times per month, 3=1–2 times per week, 4=3–4 times per week, 5=almost daily) in the last 
month. Alcohol and tobacco use were also recorded.
2.3 MRI scans
Scanning was performed at eight sites. Five sites (UCLA, Emory, Harvard, UNC, and Yale) 
used Siemens-Trio 3T scanners, two sites (Zucker-Hillside Hospital and UCSD) used GE 
HDx scanners, and one site (Calgary) used a GE Discovery scanner. All Siemens sites used a 
12-channel head coil and all GE sites used an 8-channel head coil. Sequence parameters 
were optimized for each scanner manufacturer, software version and coil configuration 
according to the ADNI protocol (http://adni.loni.usc.edu/methods/documents/mri-
protocols/). Scans were acquired in the sagittal plane with a 1 mm * 1 mm in-plane 
resolution and 1.2 mm slice thickness. Siemens scanners used an MPRAGE sequence with a 
256 (axial) × 240 (sagittal) × 176 (coronal) mm field of view, TR/TE/TI=2300/2.91/900 ms 
and a 9 degree flip angle, while GE scanners used an IR-SPGR sequence with a 26 cm field 
of view, TR/TE/TI=7.0/minimum full/400 ms and an 8 degree flip angle.
2.4 Image Processing
Subcortical volumetric segmentation of the thalamus was processed using FreeSurfer 
version 5.2 (http://surfer.nmr.mgh.harvard.edu/) at Yale University by investigators who had 
participated in the FreeSurfer training course at the Martinos Center for Biomedical 
Imaging. The subcortical segmentation procedure assigns a neuroanatomical label to each 
voxel of the MRI volume using a probabilistic atlas and a Bayesian classification rule (Fischl 
et al., 2002). See Cannon et al. (2014) for details on the quality assurance procedure.
2.5 Statistical Analyses
A regression analysis adjusted “raw” ROI volumes for normal variation in age based on 
observed relationships of the ROIs with age in the HC sample (Mathalon et al., 2003; 
Pfefferbaum et al., 1995). Specifically, for each ROI, volumetric data were linearly regressed 
on age in the HC group, and the resulting regression equation was used to derive predicted 
ROI volumes based on age for all subjects. These age-specific predicted volumes were then 
subtracted from observed volumes, and the difference was divided by the standard error of 
regression from the HC age-regression model. This resulted in an age-adjusted z-score for 
each participant based on the normative data provided by the HC group. By definition, the 
mean ± standard deviation for age-adjusted z-scores in the HC group equals 0 ± 1. For CHR 
participants, z-scores provide volume estimates relative to that which would be expected 
from healthy individuals of a particular age. For all groups, z-scores express deviations of 
ROI volumes from the age-specific normative ROI volume estimates in standard units. 
Accordingly, the profile of ROI z-score means for the HC’s used herein in group 
comparisons was nearly flat (i.e., all ROI means equal to zero), and the profile of the CHR 
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group reflects regional variation in the extent of volumetric abnormalities. Use of z-scores 
enabled comparison of MRI data across groups with different mean ages and across brain 
regions with fundamentally different sizes, rendering the ROI measures commensurable for 
comparison of ROI profiles between groups.
Differences in profiles of ROI volume age-adjusted z-scores (thalamus, hippocampus, 
amygdala) were evaluated in 1) all CHR and HC participants, and 2) CHR cannabis users vs. 
CHR non-users. The Subject Type effect was defined as CHR vs. HC participants, the 
Cannabis effect was defined as CHR cannabis user vs. CHR non-user, and ROI was defined 
as thalamus, hippocampus and amygdala. Difference in ROIs for CHR cannabis users and 
CHR non-users was assessed with the interaction effect (ROI × Cannabis) of a mixed model 
analysis of variance (ANOVA) with scanner site entered as an additional between-subjects 
factor to control for any potential site variation in MRI volumes. All imaging analyses 
included intracranial volume as a covariate. Chi-square for categorical variables and t-tests 
for continuous variables were used to compare CHR and HC groups on demographics and 
cannabis use. Chi-squares and ANOVAs were used to compare cannabis users and non-users 
on demographic and substance use variables. The critical p-value was set to p=0.05.
2.6 Procedures
All eight NAPLS sites (Emory University, Harvard University, University of Calgary, 
University of California at Los Angeles, University of California at San Diego, University of 
North Carolina at Chapel Hill, Yale University, and Zucker Hillside Hospital) recruited CHR 
and HC individuals. Raters were experienced research clinicians who demonstrated adequate 
reliability at routine reliability checks. Gold standard post-training agreement on the critical 
threshold for determining initial eligibility and subsequent conversion status based on the 
SIPS was excellent (kappa=.90). The Principal Investigator/psychiatrist/psychologist at each 
site conducted a comprehensive clinical assessment to determine if entry criteria were met. 
JA chaired weekly conference calls to review criteria for all individuals admitted to the 
study. Clinical assessments that included the AUS/DUS were conducted at baseline. The 
study protocols and informed consents were reviewed and approved by the ethical review 
boards of all eight NAPLS study sites.
3. Results
3.1 Demographics and cannabis use patterns
Demographic and clinical characteristics, as well as mean substance use ratings of CHR and 
HC participants are summarized in Table 1. Compared to the HC group, the CHR group was 
significantly younger, had fewer years of education, and had relatively more males. Groups 
did not differ on racial background. CHR participants had significantly higher cannabis use 
severity and frequency, lower alcohol use and higher tobacco use than HC participants.
One-hundred thirty-two CHR participants used cannabis (i.e. scored ‘2’ or higher on the 
AUS/DUS severity scale) at baseline. Demographic and clinical characteristics, as well as 
mean substance use ratings of CHR cannabis users vs. non-users and HC non-users are 
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summarized in Supplementary Table 1. CHR cannabis users and CHR non-users 
significantly differed on education, and alcohol and tobacco use.
3.2 Regional brain volume differences
Volumetric analysis was conducted on age-adjusted z-scores. Group means for the cortical 
gray matter ROI raw volumes, although not analyzed statistically, are presented in Table 2.
First, we examined volumetric differences in our 3 a priori ROIs in all CHR participants 
compared to HC participants, to evaluate baseline differences across groups. As shown in 
Table 3, the main effect of ROI was significant, indicating significantly larger thalamus 
compared to both hippocampus and amygdala, and larger hippocampus than amygdala, 
Main effects of Subject Type and Site were non-significant. The ROI × Site effect was 
significant, which may have been related to scanner differences or subject cohort differences 
between sites. All other effects in the model controlled for these Site effects. The ROI × 
Subject Type effect was non-significant. Thus CHR and HC participants did not differ on 
volumes of thalamus, hippocampus or amygdala.
Secondly, to evaluate our hypothesis that CHR cannabis users would show significantly 
smaller thalamic volumes compared to CHR non-users, we evaluated volumetric differences 
in the 3 ROIs amongst these two CHR groups. These results are displayed in Table 4. Main 
effects of ROI and Site were non-significant. A significant main effect of Cannabis was seen. 
The ROI × Site interaction was significant; all other effects in the model controlled for Site 
effects. A significant ROI × Cannabis effect can be seen. Follow-up tests to parse this 
interaction showed that the Cannabis effect was significant for the amygdala, but not for the 
other ROIs, with cannabis users having significantly smaller amygdala than non-users (see 
Figure 1). Further follow-up tests indicated a significant ROI effect in CHR non-users, 
reflecting significantly larger hippocampus than amygdala. The ROI effect was non-
significant among CHR cannabis users.
We re-ran this latter analysis after removing 15 CHR cannabis users and 88 non-users who 
were taking antipsychotic medication. The results changed such that the ROI X Cannabis 
interaction went from p=0.03 to 0.10. Follow-up tests indicated that the cannabis effect for 
amygdala went from 0.03 to 0.01, reflecting significantly smaller amygdala volumes but not 
hippocampal or thalamic volumes (p=0.13 and p=0.66, respectively) in CHR cannabis users 
compared to CHR non-users.
When entering tobacco use as a statistical covariate in the repeated measures ANOVA, the 
ROI X Cannabis interaction was reduced to a trend, F(2,507)=2.72, p=0.07. Follow-up tests 
indicated significantly smaller amygdala in CHR cannabis users compared to non-users 
(p=0.04), but no difference in hippocampal or thalamic volumes (p=0.08 and p=0.98, 
respectively).
Finally, we re-ran the analysis presented in Table 4, but this time included only CHR 
participants who endorsed using alcohol at the ‘use without impairment’ severity level, to 
account for potential effect of alcohol use on observed effects reported above. This subgroup 
was selected as there were large and relatively similar sample sizes of people who endorsed 
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alcohol use without impairment amongst CHR cannabis users (n=100) and CHR cannabis 
nonusers (n=110, see Supplementary Table 1); in comparison, number of CHR cannabis 
users and CHR non-users were quite diverse in proportion of individuals who were abstinent 
from alcohol use or used with abuse or dependence. The results indicated that the ROI X 
Cannabis interaction was statistically significant at p=0.03. However, follow-up tests 
indicated that the cannabis effect for amygdala went from 0.02 to 0.10, reflecting a trend 
toward smaller amygdala volumes in CHR users compared to CHR non-users. A significant 
effect was observed for the hippocampus (p=0.007), reflecting significantly smaller 
hippocampus in CHR cannabis users compared to CHR non-users, and no difference in 
thalamic volumes (p=0.94). See Figure 2.
In a final analysis, we re-ran this same analysis in all CHR cannabis users (n=132) and all 
CHR non-users (n=387), entering alcohol use and tobacco use as statistical covariates. The 
results changed such that the ROI X Cannabis interaction was non-significant, 
F(2,506)=2.16, p=0.12, indicating that CHR cannabis users and non-users did not 
significantly differ on volumes of any subcortical structure.
4. Discussion
The current study evaluated thalamic, hippocampal and amygdala volumes in a large sample 
of people at CHR of psychosis who used cannabis compared to CHR non-users. Our first 
analysis showed that CHR and HC participants did not significantly differ on volumes of any 
ROI. Our second analysis showed that CHR cannabis users had significantly smaller 
amygdala volumes, but not hippocampal or amygdala volumes, compared to CHR non-
users. Covarying for tobacco use reduced this effect to a trend. When results were limited to 
CHR participants who endorsed using alcohol without impairment, the smaller amygdala in 
CHR cannabis users was no longer seen, and a significant effect emerged such that CHR 
cannabis users showed significantly smaller hippocampal volumes compared to CHR non-
users. This suggests that alcohol use may have confounded the observed effect between 
cannabis use and smaller amygdala volumes in the CHR group, and that CHR cannabis users 
show smaller hippocampi compared to CHR non-users when restricting analyses to CHR 
subjects who use alcohol at a ‘use without impairment’ severity level.
The finding that CHR cannabis users showed reduction in hippocampal volumes compared 
to CHR non-users after being matched on alcohol use patterns is consistent with the results 
of one study that used automated tensor-based morphometry analysis to detect gray matter 
loss in right anterior hippocampus in individuals at genetic risk of schizophrenia who 
endorsed using cannabis over a 2-year period (Welch et al., 2013). Individuals with heavy 
cannabis use and otherwise minimal psychiatric comorbidities show morphologic reductions 
in the hippocampus (Lorenzetti et al., 2015), and dose-related reductions in hippocampal 
volume have been seen in otherwise healthy chronic cannabis users (Yucel et al., 2008). The 
hippocampus is one brain regions reported as abnormal in people with schizophrenia and in 
those at risk of psychosis (Fusar-Poli et al., 2012b; Olabi et al., 2011). One study has 
reported that people with schizophrenia who use cannabis show hippocampal shape 
deflation compared to healthy controls (Solowij et al., 2013), and another documented 
decreased left hippocampal volumes in cannabis using patients with a first-episode 
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psychosis (Bangalore et al., 2008). Hence these findings are consistent with those of the 
current study, which suggest that individuals at CHR of psychosis may have an enhanced 
sensitivity to the effects of cannabis on subcortical brain structure, or that volumetric 
reductions in hippocampus may confer greater risk of cannabis use in this population. 
However, here it is critical to note that once the joint effects of alcohol and tobacco were 
accounted for, CHR cannabis users and CHR non-users did not significantly differ on 
volumes of hippocampus or amygdala. This finding highlights the importance of controlling 
for residual confounding effects of other substance use when evaluating the covariation 
between cannabis use and neuroanatomy.
It should be noted that two previous studies in people at genetic risk for schizophrenia 
showed marked reductions in thalamic volumes in those who consumed cannabis over a 2-
year period (Welch et al., 2011b), and an enlarged third ventricle in frequent users compared 
to other use frequencies which could reflect gray matter loss in the adjacent anterior medial 
thalamus (Welch et al., 2011a), and this effect was not observed here. One possibility is that 
there is something specific about being at familial risk for schizophrenia and its relationship 
with cannabis use and thalamic volumes. There is some support for this hypothesis in the 
work of Habets and colleagues (Habets et al., 2011) who reported a significant group X 
cannabis interaction effect, with robust reductions of cortical thickness for people with 
schizophrenia and their healthy siblings than controls, suggesting genetic liability and 
cannabis use interaction effects on cortical thickness. Another possibility is that chronic and 
heavy cannabis use can lead to progressive structural changes in people at risk of psychosis. 
In previous studies in individuals at familial risk of schizophrenia, cannabis exposure was 
reported dichotomously (Yes/No) and the number of exposures was not reported. It can be 
seen that in our study most participants (74%) were abstinent from cannabis, and the 
majority of CHR participants who endorsed using cannabis at the baseline assessment had 
very low use severity (21%) and only 4.4% met criteria for abuse or dependence. Thus it is 
possible that evaluating samples of people at CHR of psychosis with greater proportions of 
heavy cannabis users may reveal different effects for volumes of the thalamus, hippocampus 
and amygdala. Indeed, literature in people with schizophrenia has revealed that heavy 
cannabis users show thalamic shape differences (Smith et al., 2014) and volumetric 
reductions in hippocampus and amygdala (Lorenzetti et al., 2015). Future research may 
consider evaluating CHR heavy cannabis users vs. recreational users vs. non-users on 
subcortical volumes to further understand the relationship between neuroanatomy and 
varying levels of cannabis use severity.
Several limitation should be noted. The self-report ascertainment of cannabis use may be 
less reliable gathering biologically based metrics such as urine toxicology data to verify 
cannabis use. A recent study evaluating concordance between urine screening and self-
reported cannabis use in youth at risk for psychosis has shown inconsistencies between urine 
results and self-reported use, such that some people reported cannabis usage but urine 
screens were negative, whereas others did not report cannabis use but urine screens were 
positive for tetrahydrocannabinol (Carol and Mittal, 2014). Further, details on cannabis 
dosage or potency were not collected and therefore their potential impact on subcortical 
structure cannot be determined. Importantly, the present cross-sectional analysis cannot infer 
causality between cannabis use patterns and morphology of subcortical structures. Rather, 
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our cross-sectional analysis only presents a snapshot of the association between cannabis 
and brain structure, by suggesting smaller amygdala in CHR cannabis users compared to 
CHR non-users, and smaller hippocampi amongst CHR cannabis users with minimal alcohol 
use compared to CHR non-users with equivalent alcohol use. Longitudinal studies are 
clearly required to dissociate trait characteristics from the effects of substance use on the 
brain. The current sample of CHR individuals is highly representative of recreational 
cannabis users rather than heavy and problematic users, and this should be considered when 
comparing the present results to previously published studies in schizophrenia. 
Unfortunately, we did not have a representative sample size of healthy control cannabis users 
to evaluate whether observed differences are due to a combination of cannabis use and CHR 
status, or of cannabis use alone. Future research should aim to address this important 
question by recruiting healthy controls who also endorse cannabis use. The present analysis 
did not factor in the contribution of other SCID-IV diagnoses to the results, and thus we are 
unable to identify to the specific role of other diagnoses or their interaction with cannabis 
use patterns and subcortical brain structure in the CHR sample. The current work extends 
knowledge on the relationship between cannabis and brain structure by showing that 
cannabis use is associated with smaller hippocampal volumes after controlling for alcohol 
use in youth at CHR of psychosis. However this manuscript also highlights the importance 
of controlling for effects of other substance use when evaluating the association between 
cannabis and neural structure.
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Highlights
• Cannabis use measured in youth at clinical high risk (CHR) of 
psychosis
• Subcortical volumes compared in CHR subjects who used cannabis vs. 
non-users
• CHR cannabis users showed significantly smaller amygdala compared 
to non-users
• Among light alcohol users, smaller hippocampi in CHR cannabis users 
vs. non-users
• Controlling for alcohol and tobacco rendered these effects non-
significant
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Figure 1. 
Estimated marginal means of age-corrected z-scores for clinical high risk cannabis users 
(n=132) and cannabis non-users (n=387) for thalamus, hippocampus and amygdala, adjusted 
for intracranial volume. Significantly smaller amygdala volumes were seen in CHR cannabis 
users compared to CHR non-users. Dotted line represents the approximate mean value of 
healthy controls.
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Figure 2. 
Estimated marginal means of age-corrected z-scores for clinical high risk participants who 
endorsed using alcohol at a ‘use without impairment’ severity level (cannabis users, n=100, 
and cannabis non-users, n=110) for thalamus, hippocampus and amygdala, adjusted for 
intracranial volume. Significantly smaller hippocampi were seen in CHR cannabis users 
compared to CHR non-users. Dotted line represents the approximate mean value of healthy 
controls.
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Table 2
Volumes of 3 subcortical regions of interest.
CHR HC
User n=132 Non-user n=387 Non-user n=204
Thalamus 15735.7 ± 1660.9 15362.7 ± 1783.6 15432.6 ± 1588.7
Hippocampus 8442.7 ± 893.0 8454.8 ± 904.5 8536.8 ± 876.1
Amygdala 3454.5 ± 435.4 3486.0 ± 474.4 3469.4 ± 421.4
Note. Data are shown as mean ± standard deviation. HC = Healthy Control; CHR = Clinical High Risk.
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Table 3
Analysis of variance (ANOVA) of thalamus, hippocampus and amygdala in CHR and HC participants.
Effect df F p-value
ROI 2 16.13 <0.001 Thalamus > Hippocampus
Thalamus > Amygdala
Hippocampus > Amygdala
Subject type 1 2.29 0.13
Site 7 1.89 0.07
ROI × Site 14 8.74 <0.001
ROI × Subject Type 2 1.23 0.29
Note. Subject type = healthy control or clinical high risk, collapsed across cannabis users and non-users. ANOVA results are based on multivariate 
assumptions for repeated measures, and all F-tests are based on Wilks’ Lambda. Significant p-values are bolded. Follow-up tests are shown in 
italics.
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Table 4
Analysis of variance (ANOVA) of thalamus, hippocampus and amygdala in CHR cannabis users (n=132) vs. 
CHR non-users (n=387).
Effect df F p-value Direction of effect
ROI 2 9.86 <0.001
Cannabis 1 4.40 0.04
Site 7 0.92 0.49
ROI × Site 14 6.49 <0.001
ROI × Cannabis 2 3.46 0.03
 Cannabis effect for thalamus 1 0.21 0.65
 Cannabis effect for hippocampus 1 1.44 0.23
 Cannabis effect for amygdala 1 4.78 0.03 Users < Non-users
 ROI effect in users 2 0.09 0.91
 ROI effect in non-users 2 11.4 <0.001 Hippocampus > Amygdala
Note. HC = Healthy Control; CHR = Clinical High Risk; Cannabis = cannabis user or non-user. ANOVA results are based on multivariate 
assumptions for repeated measures, and all F-tests are based on Wilks’ Lambda. Follow-up ANOVAs are shown in italics. Significant p-values are 
bolded.
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